Managing Abnormal Uterine Bleeding During Anticoagulant Therapy in Clinical Practice
Thrombosis and Haemostasis · 06.11.2026
DOI: 10.1055/a-2998-7831 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 06.11.2026. Verfasst von Gabrielle Sarlon und 10 weiteren Autor:innen. Beteiligte Einrichtung: AP-HM, Vascular Medicine and Arterial Hypertension Departement, Provence-Alpes-Côte d'Azu, France, Marseille Cedex 5. Gefördert von: Pfizer, Bristol-Myers Squibb.
Abstract (Originalsprache)
Anticoagulant therapies, including heparins, vitamin K antagonists, and direct oral anticoagulants (DOACs) such as rivaroxaban, apixaban and dabigatran, are crucial for the treatment and the prevention of venous thromboembolism (VTE). While DOACs offer improved safety profiles, their use, espe-cially in women of reproductive age, increases the risk of abnormal uterine bleeding (AUB), partic-ularly heavy menstrual bleeding (HMB). HMB, defined as blood loss exceeding 80 mL per cycle or causing significant life disruption, is associated with reduced quality of life and substantial economic costs. Women on anticoagulants report higher incidences of HMB, often requiring adjustments in therapy or additional interventions. Management strategies include the referral for a gynecological consultation, the adjustment of hormonal therapy and anticoagulant treatment, the administration of tranexamic acid, and the treatment of iron deficiency. The review underscores the importance of a comprehensive, personalized approach to managing AUB in women on anticoagulants to optimize both anticoagulation effectiveness and patient quality of life.
Autor:innen und Institutionen
- AP-HM, Vascular Medicine and Arterial Hypertension Departement, Provence-Alpes-Côte d'Azu, France, Marseille Cedex 5.
- Université Paris decartes, Hematology, Paris, France, Paris.
- AP-HP, European Hospital Georges Pompidou, Hematology, Paris, France.
- University HOSPITAL North, Gynecology-obstetrics, Cedex 2, France, Saint Etienne.
- INSERM U1059, Saint-Etienne, F-42023, France; University of Lyon, Saint-Etienne, F-42023, France, France.
- Nancy University Hospital Center, Department of Obstetrics and Fetal Medicine, Grand Est, France, Nancy.
ORCID-Profile: Nicolas Gendron, Isabelle Mahé
Förderung
- Pfizer
- Bristol-Myers Squibb
Zitieren
APA
Sarlon, G., Gendron, N., Chauleur, C., Zuily-Lamy, C., Mahé, I., Sevestre-Pietri, M. A., Tromeur, C., Couturaud, F., Trillot, N., Agostini, A., & Morange, P. E. (2026). Managing Abnormal Uterine Bleeding During Anticoagulant Therapy in Clinical Practice. Thrombosis and Haemostasis. https://doi.org/10.1055/a-2998-7831
Vancouver
Sarlon G, Gendron N, Chauleur C, Zuily-Lamy C, Mahé I, Sevestre-Pietri MA, et al. Managing Abnormal Uterine Bleeding During Anticoagulant Therapy in Clinical Practice. Thrombosis and Haemostasis. 2026. doi:10.1055/a-2998-7831
BibTeX
@article{Sarlon2026,
author = {Sarlon, Gabrielle and Gendron, Nicolas and Chauleur, Céline and Zuily-Lamy, Catherine and Mahé, Isabelle and Sevestre-Pietri, Marie-Antoinette and Tromeur, Cecile and Couturaud, Francis and Trillot, Nathalie and Agostini, Aubert and Morange, Pierre Emmanuel},
title = {Managing Abnormal Uterine Bleeding During Anticoagulant Therapy in Clinical Practice},
journal = {Thrombosis and Haemostasis},
year = {2026},
doi = {10.1055/a-2998-7831}
}
EUVIMED